nelarabine (arranon) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Arranon is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. It is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. Administration of nelarabine in combination with adenosine deaminase inhibitors, such 195 as pentostatin, is not recommended. The most common (≥20%) adverse reactions were: anemia, thrombocytopenia, neutropenia, nausea, diarrhea, vomiting, constipation, fatigue, pyrexia, cough, and dyspnea   NCATS

  • SMILES: COC1=NC(N)=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O
  • Mol. Mass: 297.2673
  • ALogP: -1.97
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$65.6684 - $86.8248
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-amino-6-methoxypurine arabinoside | 2-amino-9-beta-d-arabinofuranosyl-6-methoxy-9h-purine | 506u | 506u78 | arranon | atriance | compound 506u78 | glaxosmithkline brand of nelarabine | gw506u78 | may | nelarabine | nelzarabine


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue